Overexpression of miR-219 as a potential therapeutic strategy of glioblastoma cells in vitro
Maja Petrović, Simona Lapčević, Ivana Z Matić, Luka Bojić, Marina Nikitović, Tatjana Stanojković, Danijela Stanisavljević Ninković · 2026
Read Overexpression of miR-219 as a potential therapeutic strategy of glioblastoma cells in vitro by Maja Petrović, Simona Lapčević, Ivana Z Matić, Luka Bojić, Marina Nikitović, Tatjana Stanojković, Danijela Stanisavljević Ninković (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13486710.txt.
Description
Petrović and colleagues boosted a small RNA molecule inside glioblastoma cells to test whether it can strengthen standard treatment for this brutal brain cancer. Median survival stays under fifteen months despite surgery, radiation, and the drug temozolomide. Their 2026 study raised levels of the molecule, miR-219, in tumor cells grown flat and as three-dimensional spheres, then combined it with radiation and the standard drug.
Extra miR-219 dialed down two target genes linked to tumor growth, REST and AKAP13, in the treated cells. Treated cells lost malignant behaviors, growing and invading less than untreated controls in the assays reported. Spheres of tumor cells also died more readily when miR-219 joined radiation or drug treatment. Petrović frames miR-219 replacement as a candidate add-on therapy, while stressing that all evidence so far comes from laboratory cultures.
Catalog record
| CREATOR | Maja Petrović, Simona Lapčević, Ivana Z Matić, Luka Bojić, Marina Nikitović, Tatjana Stanojković, Danijela Stanisavljević Ninković |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |